Roth Capital Estimates biote's Q1 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD - Free Report) - Analysts at Roth Capital dropped their Q1 2025 earnings per share (EPS) estimates for shares of biote in a research note issued to investors on Thursday, March 13th. Roth Capital analyst G. Kelly now forecasts that the company will post earnings per share of $0.09 for the quarter, down from their previous forecast of $0.13. The consensus estimate for biote's current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote's Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.53 EPS and FY2026 earnings at $0.70 EPS.

Separately, Craig Hallum decreased their price objective on biote from $12.00 to $8.00 and set a "buy" rating for the company in a research note on Thursday, March 13th.

biote Stock Up 1.8 %

BTMD stock traded up $0.07 during midday trading on Friday, reaching $4.07. 231,877 shares of the company's stock traded hands, compared to its average volume of 176,962. The company has a 50-day simple moving average of $4.92 and a two-hundred day simple moving average of $5.53. biote has a 1-year low of $3.04 and a 1-year high of $8.44. The company has a market cap of $221.15 million, a price-to-earnings ratio of 15.65 and a beta of 1.07.

Insiders Place Their Bets

In other news, major shareholder Guines Llc purchased 750,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the acquisition, the insider now directly owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. This trade represents a 24.42 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 13.90% of the company's stock.

Remove Ads

Institutional Trading of biote

A number of institutional investors have recently modified their holdings of BTMD. Price T Rowe Associates Inc. MD bought a new stake in shares of biote in the fourth quarter valued at about $67,000. Commonwealth Equity Services LLC bought a new stake in shares of biote in the fourth quarter valued at about $68,000. Public Employees Retirement System of Ohio acquired a new stake in shares of biote in the fourth quarter valued at about $69,000. Intech Investment Management LLC acquired a new stake in shares of biote in the fourth quarter valued at about $71,000. Finally, SG Americas Securities LLC acquired a new stake in shares of biote in the fourth quarter valued at about $76,000. 21.68% of the stock is currently owned by institutional investors.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.